(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 March 2005 (31.03.2005)

PCT

(10) International Publication Number
WO 2005/028484 A1

(51) International Patent Classification[7]: C07D 513/04, A61K 31/4353, 31/4365

(21) International Application Number:
PCT/EP2004/010179

(22) International Filing Date:
11 September 2004 (11.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03021119.7 19 September 2003 (19.09.2003) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **NORCROSS, Roger, David** [GB/CH]; Alte Saline 20, CH-4310 Rheinfelden (CH).

(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124, CH-4072 Basel (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS



(I)

(57) **Abstract:** The present invention relates to compounds of the general formula (I) wherein R^1 is morpholin-4-yl, phenyl or tetrahydropyran-4-yl; R^2 is $-(CH_2)_n$-aryl, unsubstituted or substituted by one or more substituents, selected from the group consisting of halogen, lower alkoxy, lower alkyl, $-(CH_2)_n$ NR'R", -0 $(CH^2)_n$-O -lower alkyl, or $-(CH_2)_n$-heterocyclyl, or is heteroaryl, unsubstituted or substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, $-(CH_2)_n$ NR'R", $-(CH_2)_n$-heterocyclyl, which is optionally substituted by hydroxy or lower alkoxy, or is $-(CH_2)_n$-heterocyclyl, optionally substituted by one or more substituents selected from the group consisting of $-(CH_2)_n$,-OH, $-(CH_2)_n$-O-lower alkyl or lower alkyl, or is $-(CH_2)_n$-cycloalkyl, or is - $(CH_2)_n$,-O -lower alkyl, or is NR'R'', or is benzo[1,3]dioxole, 2-methyl-l-oxo-2,8-diaza-spiro[4,5] decane, 2-oxa-5-azabicyclo [2.2.1]heptane or I-oxa-8-aza-spiro[4.5]decane; R',R" are independently from each other lower alkyl, - $(CH_2)_n$,-O -lower alkyl or cycloalkyl, optionally substituted by hydroxy; n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. These compounds may be used in the control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or against asthma, allergic responses, hypoxia, ischaernia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardiaprotective agents for disorders such as coronary artery disease and heart failure. The most preferred indications in accordance with the present invention are those which include disorders of the central nervous system, for example the treatment or prevention of Alzheimer's disease, certain depressive disorders, drug addiction, neuroprotection and Parkinson's disease as well as ADHD.

WO 2005/028484 A1